necrosis quantitation kit plus  (Biotium)

Journal: Neural Regeneration Research

Article Title: Sox2-overexpressing neural stem cells alleviate ventricular enlargement and neurological dysfunction in posthemorrhagic hydrocephalus

doi: 10.4103/NRR.NRR-D-24-01491

Figure Lengend Snippet: NSC Sox2 transplantation decreases the expression of proinflammatory factors and increases the expression of anti-inflammatory factors and neurotrophic factors in hippocampus. (A, B) ELISA results of TNF-α (A) and IL-1β (B) in hippocampus. (C) Typical western blot bands of TNF-α, IL-6, IL-10, BDNF, and NGF. (D) Statistical analysis of proteins. All data are presented as the mean ± SD ( n = 5). ** P < 0.01, *** P < 0.001, vs . Sham group (one-way analysis of variance followed by post hoc Tukey’s honestly significant difference test). BDNF: Brain-derived growth factor; ELISA: enzyme-linked immunosorbent assay; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL: interleukin; IVH: intraventricular hemorrhage; NGF: nerve growth factor; NSC: neural stem cell; PBS: phosphate-buffered saline; SD: standard deviation; Sox2: sex-determining region Y-box 2; TNF-α: tumor necrosis factor-alpha.

Article Snippet: The supernatant was collected for the assay using enzyme-linked immunosorbent assay (ELISA) kits (EK0527, EK0394, Boster Bio, Anaheim, CA, USA).

Techniques: Transplantation Assay, Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, Derivative Assay, Saline, Standard Deviation

Journal: PLOS One

Article Title: Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV

doi: 10.1371/journal.pone.0338127

Figure Lengend Snippet: A. Competitive ELISA assessing the binding of His-tagged IgGs to immobilized HER2 in the presence or absence of saturating concentrations of non-His-tagged IgGs, detected with an anti-His-HRP antibody. B. Saturation binding curves of trastuzumab and pertuzumab to HER2 on live MCF7 cells. Cells were incubated with antibodies (0-400 nM) for 30 min and detected with an AF647-conjugated goat anti-human secondary antibody via flow cytometry. C. Competitive binding of of AF647-labeled trastuzumab or pertuzumab (0-300 nM) to MCF7 cells pre-saturated with 267 nM of unlabeled trastuzumab and pertuzumab, analyzed by flow cytometry. D. Binding of AF647-conjugated m66 or m75 to MCF7 cells after pre-incubation with 267 nM trastuzumab or pertuzumab. E. Binding of AF647-conjugated rabbit antibodies to MCF7 cells pre-saturated with 267 nM of trastuzumab and pertuzumab, evaluated by flow cytometry. T, trastuzumab; P, pertuzumab. Error bars, SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, T-test.

Article Snippet: Briefly, each antibody was reacted with 20 molar equivalents of AF647 NHS ester (Biotium, 30–3007) for 2 h at room temperature protected from light.

Techniques: Competitive ELISA, Binding Assay, Incubation, Flow Cytometry, Labeling